Disruptions due to COVID-19 paired with a slew of new guidance from regulatory bodies has catapulted the clinical trial industry into a period of digital transformation.1 More sponsors and CROs are beginning to adopt decentralized solutions and embrace digital workflows, yet informed consent continues to rely heavily on paper-based processes. Lots and lots of paper.